Literature DB >> 10854533

Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues.

R Yamaguchi1, H Yano, Y Nakashima, S Ogasawara, K Higaki, J Akiba, D J Hicklin, M Kojiro.   

Abstract

Flt-1 (VEGF receptor-1) and KDR/Flk-1 (VEGF receptor-2) are the high-affinity receptors for the angiogenesis factor, vascular endothelial growth factor (VEGF). VEGF expression has been confirmed in human hepatocellular carcinoma (HCC), and VEGF is thought to be involved in the angiogenesis within HCC tissues. However, expressions of VEGF receptors in HCC have not been reported. We immunohistochemically examined expressions and localizations of Flt-1 and KDR in 28 surgically resected HCC tissues. In non-cancerous area, Flt-1 and KDR were mainly found in macrophages including Kupffer cells; both receptors were found in vascular endothelial cells in the portal veins and arteries within portal tracts; and KDR was also found in some sinusoidal endothelial cells. In cancerous area, Flt-1 and KDR were found in some macrophages, and also in the endothelial cells of intratumoral blood vessels. In 25 moderately and/or poorly differentiated HCCs, KDR expression in the blood space endothelial cells was clear and continuous in 20 cases, and focal in 5 cases. These results suggest that there would be an angiogenesis mechanism via VEGF/Flt-1 or VEGF/KDR in HCC, and the VEGF/KDR system would take a more important role.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854533     DOI: 10.3892/or.7.4.725

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

1.  Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues.

Authors:  Shao-Hua Peng; Hong Deng; Jian-Feng Yang; Ping-Ping Xie; Cheng Li; Hao Li; De-Yun Feng
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

2.  New agents on the horizon in hepatocellular carcinoma.

Authors:  Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

3.  Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma.

Authors:  Zhong-Lin Zhang; Zhi-Su Liu; Quan Sun
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

4.  Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent.

Authors:  Laure S Fournier; Charles Andre Cuenod; Cedric de Bazelaire; Nathalie Siauve; Christophe Rosty; Phuong Lan Tran; Guy Frija; Olivier Clement
Journal:  Eur Radiol       Date:  2004-07-29       Impact factor: 5.315

5.  The patterns and expression of KDR in normal tissues of human internal organs.

Authors:  Jianfei Huang; Huijun Zhu; Xudong Wang; Qi Tang; Hua Huang; Kerong Wu; Jin Zhu; Zhenqing Feng; Gongshen Shi
Journal:  J Mol Histol       Date:  2011-09-10       Impact factor: 2.611

6.  Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.

Authors:  Zhong-Lin Zhang; Zhi-Su Liu; Quan Sun
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

7.  Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

Authors:  El Mehdi Tazi; Ismail Essadi; Hind M'rabti; Anass Touyar; Pr Hassan Errihani
Journal:  N Am J Med Sci       Date:  2011-04

8.  Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma.

Authors:  Kai Liu; Xu He; Xue-Zhong Lei; Lian-San Zhao; Hong Tang; Li Liu; Bing-Jun Lei
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 9.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 10.  Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Cancer J       Date:  2009 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.